Editas Medicine

Editas Medicine is a clinical-stage genome editing company dedicated to developing transformative CRISPR-based medicines for severe human diseases. The enterprise harnesses proprietary engineered Cas9 and Cas12a nucleases to repair defective genetic pathways across hematologic disorders and inherited conditions. Through target discovery and clinical gene editing programs, Editas Medicine develops therapies that modify human genomes to treat genetic illnesses.